[S01HA03, tetracaine, The risk or severity of methemoglobinemia can be increased when Alitretinoin is combined with Tetracaine.]
[S03AA02, tetracycline, The risk or severity of pseudotumor cerebri can be increased when Alitretinoin is combined with Tetracycline.]
[S01XA02, vitamin A, The risk or severity of adverse effects can be increased when Vitamin A is combined with Alitretinoin.]
[G03AC10, drospirenone, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Alitretinoin.]
[B03XA04, peginesatide, The risk or severity of Thrombosis can be increased when Peginesatide is combined with Alitretinoin.]
[R02AD01, benzocaine, The risk or severity of methemoglobinemia can be increased when Alitretinoin is combined with Benzocaine.]
[P03AX06, benzyl alcohol, The risk or severity of methemoglobinemia can be increased when Alitretinoin is combined with Benzyl alcohol.]
[N01BB01, bupivacaine, The risk or severity of methemoglobinemia can be increased when Alitretinoin is combined with Bupivacaine.]
[S01HA02, benoxinate, The risk or severity of methemoglobinemia can be increased when Alitretinoin is combined with Oxybuprocaine.]
[N01BX04, capsaicin, The risk or severity of methemoglobinemia can be increased when Alitretinoin is combined with Capsaicin.]
[J01AA13, eravacycline, The risk or severity of pseudotumor cerebri can be increased when Alitretinoin is combined with Eravacycline.]
[J01AA14, sarecycline, The risk or severity of pseudotumor cerebri can be increased when Alitretinoin is combined with Sarecycline.]
[J01AA15, omadacycline, The risk or severity of pseudotumor cerebri can be increased when Alitretinoin is combined with Omadacycline.]
[N01BA04, chloroprocaine, The risk or severity of methemoglobinemia can be increased when Alitretinoin is combined with Chloroprocaine.]
[J01AA11, clomocycline, The risk or severity of pseudotumor cerebri can be increased when Alitretinoin is combined with Clomocycline.]
[G03DB05, demegestone, The therapeutic efficacy of Demegestone can be decreased when used in combination with Alitretinoin.]
[G03AC09, desogestrel, The therapeutic efficacy of Desogestrel can be decreased when used in combination with Alitretinoin.]
[G03DB08, dienogest, The therapeutic efficacy of Dienogest can be decreased when used in combination with Alitretinoin.]
[R02AD04, dyclonine, The risk or severity of methemoglobinemia can be increased when Alitretinoin is combined with Dyclonine.]
[N01BB10, levobupivacaine, The risk or severity of methemoglobinemia can be increased when Alitretinoin is combined with Levobupivacaine.]
[S02DA02, cocaine, The risk or severity of methemoglobinemia can be increased when Alitretinoin is combined with Cocaine.]
[M09AX11, palovarotene, The risk or severity of adverse effects can be increased when Alitretinoin is combined with Palovarotene.]
[B03XA02, darbepoetin alfa, The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Alitretinoin.]
[J01AA01, demeclocycline, The risk or severity of pseudotumor cerebri can be increased when Alitretinoin is combined with Demeclocycline.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Alitretinoin is combined with Phenol.]
[S02DA04, dibucaine, The risk or severity of methemoglobinemia can be increased when Alitretinoin is combined with Cinchocaine.]
[L02AA01, diethylstilbestrol, The therapeutic efficacy of Diethylstilbestrol can be decreased when used in combination with Alitretinoin.]
[D04AB07, pramoxine, The risk or severity of methemoglobinemia can be increased when Alitretinoin is combined with Pramocaine.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Alitretinoin is combined with Proparacaine.]
[R06AA02, diphenhydramine, The risk or severity of methemoglobinemia can be increased when Alitretinoin is combined with Diphenhydramine.]
[N01BB09, ropivacaine, The risk or severity of methemoglobinemia can be increased when Alitretinoin is combined with Ropivacaine.]
[J01AA02, doxycycline, The risk or severity of pseudotumor cerebri can be increased when Alitretinoin is combined with Doxycycline.]
[A08AB01, orlistat, Orlistat can cause a decrease in the absorption of Alitretinoin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01AA12, tigecycline, The risk or severity of pseudotumor cerebri can be increased when Alitretinoin is combined with Tigecycline.]
[N03AG01, valproic acid, Valproic acid may increase the Pseudotumor Cerebri activities of Alitretinoin.]
[G03CA03, estradiol, The therapeutic efficacy of Estradiol can be decreased when used in combination with Alitretinoin.]
[L02AA03, ethinyl estradiol, The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Alitretinoin.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Alitretinoin is combined with Ethyl chloride.]
[M01AC06, meloxicam, The risk or severity of methemoglobinemia can be increased when Alitretinoin is combined with Meloxicam.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Alitretinoin is combined with Etidocaine.]
[G03XA02, gestrinone, The therapeutic efficacy of Gestrinone can be decreased when used in combination with Alitretinoin.]
[N01BB08, articaine, The risk or severity of methemoglobinemia can be increased when Alitretinoin is combined with Articaine.]
[G03AD01, levonorgestrel, The therapeutic efficacy of Levonorgestrel can be decreased when used in combination with Alitretinoin.]
[S02DA01, lidocaine, The risk or severity of methemoglobinemia can be increased when Alitretinoin is combined with Lidocaine.]
[J01AA04, lymecycline, The risk or severity of pseudotumor cerebri can be increased when Lymecycline is combined with Alitretinoin.]
[G03DC03, lynestrenol, The therapeutic efficacy of Lynestrenol can be decreased when used in combination with Alitretinoin.]
[N01BB03, mepivacaine, The risk or severity of methemoglobinemia can be increased when Alitretinoin is combined with Mepivacaine.]
[J01AA05, methacycline, The risk or severity of pseudotumor cerebri can be increased when Alitretinoin is combined with Metacycline.]
[L04AX03, methotrexate, Alitretinoin may increase the hepatotoxic activities of Methotrexate.]
[J01AA08, minocycline, The risk or severity of pseudotumor cerebri can be increased when Alitretinoin is combined with Minocycline.]
[B03XA03, methoxy polyethylene glycol-epoetin beta, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Alitretinoin.]
[G03DC02, norethindrone, The therapeutic efficacy of Norethisterone can be decreased when used in combination with Alitretinoin.]
[G03AC07, norgestrienone, The therapeutic efficacy of Norgestrienone can be decreased when used in combination with Alitretinoin.]
[S01AA04, oxytetracycline, The risk or severity of pseudotumor cerebri can be increased when Alitretinoin is combined with Oxytetracycline.]
[G03DB06, chlormadinone, The therapeutic efficacy of Chlormadinone can be decreased when used in combination with Alitretinoin.]
[N01BB04, prilocaine, The risk or severity of methemoglobinemia can be increased when Alitretinoin is combined with Prilocaine.]
[S01HA05, procaine, The risk or severity of methemoglobinemia can be increased when Alitretinoin is combined with Procaine.]
[J01AA09, rolitetracycline, The risk or severity of pseudotumor cerebri can be increased when Alitretinoin is combined with Rolitetracycline.]
